recent articles

The liquid biopsy has been developed by Datar Cancer Genetics to help diagnose brain tumors where a conventional biopsy is not possible. A prospective, blinded study by a research team at the Imperial College, London showed very high...

December 15, 2022 | Personalis and the University of California, San Francisco (UCSF) have announced a collaboration that will deploy a personalized liquid biopsy-based research use only (RUO) assay for a study of patients with colorectal...

nRichDX: The Revolution Circulating Free Total Nucleic Acid (cfTNA) Kit™ and cfDNA Reference Standard products are designed to advance liquid biopsy application development. IRVINE, Calif., October 24, 2022 – nRichDX® has launched...

SpIntellx: Seasoned precision healthcare executive brings deep leadership, commercial and operational experience PITTSBURGH (PRWEB) MAY 16, 2022 -- B. Dusty Majumdar, Ph.D. has been appointed as the Chief Executive Officer (CEO) of SpIntellx,...

To help build out its own portfolio of artificial-intelligence-driven pathology tests, Quest Diagnostics has enlisted the help of Paige to develop a suite of products aimed at individual clinical oncologists as well as larger biopharma...

OR

platinum partners

gold partners

Silver Partners

Media Partners